1-4 of 4
Wenli Zhang, MD
Close
Sort by
Journal Articles

Improved Safety and Efficacy of a Multi-Target Chimeric Antigen Receptor Modified T Cell Therapy (4SCAR2.0) Against Relapsed or Refractory Lymphomas

Rui Zhang, MSc, Yuhua Li, MD& PhD, Sanfang Tu, MD& PhD, Rui Huang, MD& PhD, Xun Lai, MD, Leping Zhang, MD PhD, Eugene E. Zvonkov, MD PhD, Valeriy G. Savchenko, MD PhD, Nelly G Gabeeva, PhD, Yuchen Liu, MSc, Yuchen Li, MSc, Cheng Jiao, MD PhD, Lan Deng, MD PhD, Xuan Zhou, MD, Hongyu Zhang, MD PhD, Wenli Zhang, MD, Lung-Ji Chang, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 47.
https://doi.org/10.1182/blood-2020-141515
Published: 2020
Journal Articles

First-in-Human CD4 CAR Clinical Trial on Peripheral T-Cell Lymphoma

Hongyu Zhang, MD PhD, Jia Feng, MD PhD, Wenli Zhang, MD, Qi Chen, PhD, Yuanzhen Cao, Kevin Pinz, Fang Liu, MD PhD, Yu Ma, Masayuki Wada, PhD, Yupo Ma, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2881.
https://doi.org/10.1182/blood-2019-122789
Published: 2019
Journal Articles

First-in-Human Trial of Bcma-CD19 Compound CAR with Remarkable Donor-Specific Antibody Reduction

Fang Liu, MD PhD, Hongyu Zhang, MD PhD, Xiao Wang, MD PhD, Yisong Xiong, PhD, Yuanzhen Cao, Yi Su, MD, Hai Yi, MD PhD, Jia Feng, MD PhD, Wenli Zhang, MD, Yu Ma, Masayuki Wada, PhD, Yupo Ma, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 38.
https://doi.org/10.1182/blood-2019-122964
Published: 2019
Journal Articles

Phase I/II Trial of Multi-Target Chimeric Antigen Receptor Modified T Cells (4SCAR2.0) Against Relapsed or Refractory Lymphomas

Lung-Ji Chang, PhD, Yuhua Li, MD& PhD, Sanfang Tu, MD& PhD, Xun Lai, MD, Rui Huang, MD& PhD, Shih-Ting Tsao, MSc, Yu-Chen Liu, MSc, Rui Zhang, MSc, Lan Deng, MDPhD, Xuan Zhou, MD, Hongyu Zhang, PhD MD, Wenli Zhang, MD, Yuchen Li, MSc
Journal: Blood
Blood (2018) 132 (Supplement 1): 225.
https://doi.org/10.1182/blood-2018-99-114396
Published: 2018